Compile Data Set for Download or QSAR
maximum 50k data
Found 2296 with Last Name = 'elliott' and Initial = 'r'
LigandPNGBDBM50149477(CHEMBL3770993 | US10851091, U.S. Pat. No. 8,242,10...)
Affinity DataKi:  0.0160nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM50149477(CHEMBL3770993 | US10851091, U.S. Pat. No. 8,242,10...)
Affinity DataKi:  0.0160nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD(3) dopamine receptor(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50290221(CHEMBL80919 | Thiophene-2-carboxylic acid (4-{2-[4...)
Affinity DataKi:  0.0200nMAssay Description:Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.More data for this Ligand-Target Pair
In DepthDetails Article
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295675(US10851091, U.S. Pat. No. 8,242,104 No. 469 | US82...)
Affinity DataKi: <0.0200nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295675(US10851091, U.S. Pat. No. 8,242,104 No. 469 | US82...)
Affinity DataKi: <0.0200nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295679(US10851091, U.S. Pat. No. 8,242,104 No. 529 | US82...)
Affinity DataKi:  0.0230nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295679(US10851091, U.S. Pat. No. 8,242,104 No. 529 | US82...)
Affinity DataKi:  0.0230nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50602306(CHEMBL5208487)
Affinity DataKi:  0.0260nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPlatelet-activating factor acetylhydrolase(Homo sapiens (Human))
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50117772(CHEMBL10921 | N-(2-Diethylamino-ethyl)-2-[2-(4-flu...)
Affinity DataKi:  0.0300nMAssay Description:Steady state and transient kinetics to a freely reversible, non-covalently bound, human recombinant Phospholipase A2 (rhLp-PLA2) was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM295665((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  0.0340nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
LigandPNGBDBM295665((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  0.0340nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295665((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  0.0340nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  0.0400nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  0.0400nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50602320(CHEMBL5199631)
Affinity DataKi:  0.0420nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
LigandPNGBDBM50602324(CHEMBL5198796)
Affinity DataKi:  0.0430nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295671((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  0.0480nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295671((S)-2-((2-((S)-4-(difluoromethyl)- 2-oxooxazolidin...)
Affinity DataKi:  0.0480nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295669((S)-2-cyclopropyl-2-((2-((S)-4- (fluoromethyl)-2-o...)
Affinity DataKi:  0.0510nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295669((S)-2-cyclopropyl-2-((2-((S)-4- (fluoromethyl)-2-o...)
Affinity DataKi:  0.0510nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295669((S)-2-cyclopropyl-2-((2-((S)-4- (fluoromethyl)-2-o...)
Affinity DataKi:  0.0510nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
LigandPNGBDBM50602323(CHEMBL5209168)
Affinity DataKi:  0.0530nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295667((S)-2-cyclopropyl-2-((2-((S)-4- (difluoromethyl)-2...)
Affinity DataKi:  0.0600nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM475607(US10851091, Compound 103)
Affinity DataKi:  0.0600nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
LigandPNGBDBM475607(US10851091, Compound 103)
Affinity DataKi:  0.0600nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM50602305(CHEMBL5209048)
Affinity DataKi:  0.0620nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetAlpha-1A adrenergic receptor(Rattus norvegicus (Rat))
Warner-Lambert

Curated by ChEMBL
LigandPNGBDBM29568(CHEMBL2 | PRAZOSIN | PRAZOSIN HYDROCHLORIDE | [3H]...)
Affinity DataKi:  0.0700nMAssay Description:Inhibition of [3H]- prazosin binding against Alpha-1A adrenergic receptor from rat submaxillary glandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0790nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0790nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In DepthDetails US Patent
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0790nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0900nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0900nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0900nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
LigandPNGBDBM50434806(2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-y...)
Affinity DataKi:  0.0900nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
LigandPNGBDBM50602328(CHEMBL5205438)
Affinity DataKi:  0.0950nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
LigandPNGBDBM50602326(CHEMBL5181348)
Affinity DataKi:  0.0970nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Genentech

Curated by ChEMBL
LigandPNGBDBM5446(CHEMBL553 | ERLOTINIB HYDROCHLORIDE | Erlotinib | ...)
Affinity DataKi:  0.100nMAssay Description:Inhibition of recombinant human N-terminal GST-tagged EGFR catalytic domain (669 to 1210 residues) expressed in baculovirus expression system by mass...More data for this Ligand-Target Pair
LigandPNGBDBM50602331(CHEMBL5182371)
Affinity DataKi:  0.100nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
LigandPNGBDBM50602304(CHEMBL5182339)
Affinity DataKi:  0.107nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
LigandPNGBDBM295686(US10851091, U.S. Pat. No. 8,242,104 No. 550 | US82...)
Affinity DataKi:  0.107nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295686(US10851091, U.S. Pat. No. 8,242,104 No. 550 | US82...)
Affinity DataKi:  0.107nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(3) dopamine receptor(Homo sapiens (Human))
TBA

Curated by ChEMBL
LigandPNGBDBM50063279(CHEMBL309623 | Cyclohexanecarboxylic acid {4-[2-(4...)
Affinity DataKi:  0.140nMAssay Description:Ability to displace radioligand [3H]spiperone from human dopamine D3 receptor transfected chinese hamster ovary cell membranes.More data for this Ligand-Target Pair
In DepthDetails Article
LigandPNGBDBM50602321(CHEMBL5202305)
Affinity DataKi:  0.150nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetAlpha-1B adrenergic receptor(Rattus norvegicus (rat))
Warner-Lambert

Curated by ChEMBL
LigandPNGBDBM29568(CHEMBL2 | PRAZOSIN | PRAZOSIN HYDROCHLORIDE | [3H]...)
Affinity DataKi:  0.150nMAssay Description:Inhibition of [3H]- prazosin binding against Alpha-1B adrenergic receptor from rat liverMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
LigandPNGBDBM50602329(CHEMBL5189517)
Affinity DataKi:  0.157nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295676(US10851091, U.S. Pat. No. 8,242,104 No. 486 | US82...)
Affinity DataKi:  0.186nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295676(US10851091, U.S. Pat. No. 8,242,104 No. 486 | US82...)
Affinity DataKi:  0.186nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295676(US10851091, U.S. Pat. No. 8,242,104 No. 486 | US82...)
Affinity DataKi:  0.188nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
LigandPNGBDBM50602325(CHEMBL5209394)
Affinity DataKi:  0.289nMAssay Description:Inhibition of PI3Kalpha (unknown origin) using PIP2:3PS as substrate in presence of ATP measured after 120 mins by ADP-Glo assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetNeuropeptide Y receptor type 5(Homo sapiens (Human))
Pfizer

Curated by ChEMBL
LigandPNGBDBM50128931(CHEMBL61880 | N-(9-Isobutyl-9H-carbazol-3-yl)-3-py...)
Affinity DataKi:  0.300nMAssay Description:Binding affinity towards human neuropeptide Y receptor type 5 using 125[I]-PYY as radioligandMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 2296 total ) | Next | Last >>
Jump to: